" "

New Antimicrobial Resistance Accelerator Programme launched by the Innovative Medicines Initiative (IMI)

A new Antimicrobial Resistance (AMR) Accelerator Programme as part of new Calls for proposals was launched in July by the Innovative Medicines Initiative (IMI). Of the other topics launched in the Calls, many address brain disorders (e.g. Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, major depression) and immune-mediated diseases (e.g. rheumatoid arthritis and lupus as well as inflammatory bowel diseases such as Crohn’s and colitis, and skin diseases like dermatitis and psoriasis). Among other things, the topics aim to make clinical trials more patient-centric, contribute to medicines safety, and apply blockchain technologies to the drug development and health sectors.
The Calls for proposals launched in July (IMI2 – Calls 15 and 16) have a total budget of EUR 434 million. Around half of this comes from Horizon 2020, the EU’s framework programme for research and innovation. The other half comes from EFPIA companies and IMI Associated Partners; these do not receive any funding from IMI but contribute to projects, mainly through ‘in-kind’ contributions (e.g. researchers’ time).
The aim of the new IMI AMR Accelerator is to progress the development of new medicines to treat or even prevent resistant bacterial infections in Europe and worldwide. The programme comprises three pillars. A Capability Building Network will coordinate the programme and carry out research to strengthen the scientific basis in the AMR field, while the Tuberculosis Drug Development Network will work to accelerate the discovery of new combinations of drugs to treat TB. Finally, Portfolio Building Networks will support collaborative efforts to discover, develop and advance new and innovative agents to prevent or treat AMR. The scope of the AMR Accelerator is broad; under one structure, it will address many of the scientific challenges of AMR, and it will support the development of new ways to prevent AMR (including vaccines) and treatments (including new antibiotics). More broadly, the IMI AMR Accelerator also contributes to the European action plan on AMR, which includes a chapter on boosting research, development and innovation for AMR.

www.imi.europa.eu